ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2019
CVR: 32323502
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR -1,850 and a net result of EUR 210,420 compared with EUR 371,171 the year before. Equity in the 2019 report amounted to EUR 14,404,246. The solvency ratio was 99.9%.
- Gross Profit
- EUR -1,850
- Profit/Loss
- EUR 210,420
- Equity
- EUR 14,404,246
- Total Assets
- EUR 14,411,944
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -2K EUR | 210K EUR | 14.4M EUR | 0 |
| 2018 | - | 7K EUR | 371K EUR | 14.2M EUR | 0 |
| 2017 | - | 257K EUR | -480K EUR | 13.8M EUR | 0 |
| 2016 | - | 3.2M EUR | 3.4M EUR | 14.3M EUR | - |
| 2015 | - | 5.4M EUR | 5.6M EUR | 10.9M EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2018. Gross profit came to DKK 7,218, and the net result was DKK 371,171.
About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
